Associated condition n=9 (30%) | No associated condition n=21 (70%) | p Value | |
Sex | 4 women/5 men | 10 women/11 men | NS |
Mean age (range) | 59 y (21–82) | 48 y (22–90) | NS |
Known pituitary adenoma | 1 (11%) | 5 (23.8%) | NS |
Neuro-ophthalmic deficit: | 8 (88.8%) | 17 (81.1%) | NS |
Headache | 9 (100%) | 21 (100%) | NS |
Ophthalmoplegia | 6 (66.6%) | 11 (52.4%) | NS |
Optic nerve compression | 4 (44%) | 7 (33%) | NS |
Chiasmal visual field defect | 4 (44%) | 10 (47.6%) | NS |
Altered mental status | 5 (55%) | 4 (19%) | <0.05 |
Systemic hypertension | 5 (55%) | 8 (38%) | NS |
Neuroimaging: | |||
Haemorrhage | 6 (66.6%) | 9 (42.8%) | NS |
Infarction | 3 (33.3%) | 12 (57.1%) | NS |
Prognosis: | |||
Death | 0 | 0 | NS |
Unknown | 2 (22.2%) | 7 (33.3%) | NS |
Pituitary dysfunction | 5/9 (55.5%) | 11/21 (52.4%) | NS |
Complete recovery | 2/7 (28.5%) | 10/14 (71%) | 0.06 |
Neurological sequelae | 1/7 (14.3%) | 0 (0%) | NS |
Neuro-ophthalmic sequelae | 5/7 (71.4%) | 2/14 (14.3%) | <0.01 |
Ophthalmoplegia | 1/6 (16.6%) | 2/11 (18.2%) | NS |
Severe optic neuropathy | 3/4 (75%) | 1/7 (14.3%) | <0.05 |
Visual field defect | 4/4 (100%) | 2/10 (20%) | <0.01 |
Mean delay in diagnosis (range) | 5.5 days (1–14) | 5.6 days (1–14) | NS |
Mean delay in treatment (range) | 2.2 days [0–7] | 2.2 days (0–)] | NS |
p Calculated using χ2 and Student'st tests.